|
1
|
Pitts R, Daugherty SL, Tang F, Jones P, Ho
PM, Tsai TT, Spertus J and Maddox TM: Optimal secondary prevention
medication use in acute myocardial infarction patients with
nonobstructive coronary artery disease is modified by management
strategy: Insights from the TRIUMPH Registry. Clin Cardiol. Apr
7–2017.(Epub ahead of print) doi: 10.1002/clc.22686. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Shibutani H, Akita Y, Yutaka K, Yamamoto
S, Matsui Y, Yoshinaga M, Karakawa M and Mori Y: Acute myocardial
infarction with ‘wrap around’ right coronary artery mimicking
Takotsubo cardiomyopathy: A case report. BMC Cardiovasc Disord.
16:712016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Sun HJ, Zhao MX, Ren XS, Liu TY, Chen Q,
Li YH, Kang YM, Wang JJ and Zhu GQ: Salusin-β promotes vascular
smooth muscle cell migration and intimal hyperplasia after vascular
injury via ROS/NFκB/MMP-9 pathway. Antioxid Redox Signal.
24:1045–1057. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ma SF, Luo Y, Ding YJ, Chen Y, Pu SX, Wu
HJ, Wang ZF, Tao BB, Wang WW and Zhu YC: Hydrogen sulfide targets
the Cys320/Cys529 motif in Kv4.2 to inhibit the Ito potassium
channels in cardiomyocytes and regularizes fatal arrhythmia in
myocardial infarction. Antioxid Redox Signal. 23:129–147. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Li G, Qian W and Zhao C: Analyzing the
anti-ischemia-reperfusion injury effects of ginsenoside Rb1
mediated through the inhibition of p38α MAPK. Can J Physiol
Pharmacol. 94:97–103. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wang F, Zhou H, Du Z, Chen X, Zhu F, Wang
Z, Zhang Y, Lin L, Qian M, Zhang X, et al: Cytoprotective effect of
melatonin against hypoxia/serum deprivation-induced cell death of
bone marrow mesenchymal stem cells in vitro. Eur J Pharmacol.
748:157–165. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wei N, Zhang C, He H, Wang T, Liu Z, Liu
G, Sun Z, Zhou Z, Bai C and Yuan D: Protective effect of saponins
extract from Panax japonicus on myocardial infarction: Involvement
of NF-κB, Sirt1 and mitogen-activated protein kinase signalling
pathways and inhibition of inflammation. J Pharm Pharmacol.
66:1641–1651. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Mehta PK and Griendling KK: Angiotensin II
cell signaling: Physiological and pathological effects in the
cardiovascular system. Am J Physiol Cell Physiol. 292:C82–C97.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Xiao H, Xu YN, Luo H, Chen Y, Zhang YY,
Tao L, Jiang Y and Shen XC: OMT inhibited TGF-β1-induced cardiac
fibroblast proliferation via down-regulating p38MAPK
phosphorylation in vitro. Zhongguo Zhong Yao Za Zhi. 40:2168–2173.
2015.(In Chinese). PubMed/NCBI
|
|
10
|
Blanc A, Pandey NR and Srivastava AK:
Synchronous activation of ERK 1/2, p38mapk and PKB/Akt signaling by
H2O2 in vascular smooth muscle cells:
Potential involvement in vascular disease (review). Int J Mol Med.
11:229–234. 2003.PubMed/NCBI
|
|
11
|
Bourzac C, Smith LC, Vincent P, Beauchamp
G, Lavoie JP and Laverty S: Isolation of equine bone marrow-derived
mesenchymal stem cells: A comparison between three protocols.
Equine Vet J. 42:519–527. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zhu G, Li J, He L, Wang X and Hong X:
MPTP-induced changes in hippocampal synaptic plasticity and memory
are prevented by memantine through the BDNF-TrkB pathway. Br J
Pharmacol. 172:2354–2368. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Osaki LH and Gama P: MAPKs and signal
transduction in the control of gastrointestinal epithelial cell
proliferation and differentiation. Int J Mol Sci. 14:10143–10161.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
del Barco Barrantes I and Nebreda AR:
Roles of p38 MAPKs in invasion and metastasis. Biochem Soc Trans.
40:79–84. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Miloso M, Scuteri A, Foudah D and Tredici
G: MAPKs as mediators of cell fate determination: An approach to
neurodegenerative diseases. Curr Med Chem. 15:538–548. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Arabacilar P and Marber M: The case for
inhibiting p38 mitogen-activated protein kinase in heart failure.
Front Pharmacol. 6:1022015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
O'Donoghue ML, Glaser R, Aylward PE,
Cavender MA, Crisp A, Fox KA, Laws I, Lopez-Sendon JL, Steg PG,
Theroux P, et al: Rationale and design of the LosmApimod To Inhibit
p38 MAP kinase as a TherapeUtic target and moDify outcomes after an
acute coronary syndromE trial. Am Heart J. 169:622–630.e6. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wang M, Li Z, Zhang X, Xie X, Zhang Y,
Wang X and Hou Y: Rosuvastatin attenuates atrial structural
remodelling in rats with myocardial infarction through the
inhibition of the p38 MAPK signalling pathway. Heart Lung Circ.
24:386–394. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Mitra A, Ray A, Datta R, Sengupta S and
Sarkar S: Cardioprotective role of P38 MAPK during myocardial
infarction via parallel activation of α-crystallin B and Nrf2. J
Cell Physiol. 229:1272–1282. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Li C, He J, Gao Y, Xing Y, Hou J and Tian
J: Preventive effect of total flavones of Choerospondias axillaries
on ischemia/reperfusion-induced myocardial infarction-related MAPK
signaling pathway. Cardiovasc Toxicol. 14:145–152. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Huang M, Yang D, Xiang M and Wang J: Role
of interleukin-6 in regulation of immune responses to remodeling
after myocardial infarction. Heart Fail Rev. 20:25–38. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Somasuntharam I, Yehl K, Carroll SL,
Maxwell JT, Martinez MD, Che PL, Brown ME, Salaita K and Davis ME:
Knockdown of TNF-α by DNAzyme gold nanoparticles as an
anti-inflammatory therapy for myocardial infarction. Biomaterials.
83:12–22. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Sekar D, Saravanan S, Karikalan K,
Thirugnanasambantham K, Lalitha P and Islam VI: Role of microRNA 21
in mesenchymal stem cell (MSC) differentiation: A powerful
biomarker in MSCs derived cells. Curr Pharm Biotechnol. 16:43–48.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Hu X, Chen P, Wu Y, Wang K, Xu Y, Chen H,
Zhang L, Wu R, Webster KA, Yu H, et al: MiR-211/STAT5A signaling
modulates migration of mesenchymal stem cells to improve its
therapeutic efficacy. Stem Cells. 34:1846–1858. 2016. View Article : Google Scholar : PubMed/NCBI
|
